Keros Therapeutics' (KROS) near-term upside remains limited due to uncertainty surrounding the development of its lead drug candidate, KER-065, despite an "intriguing" pipeline and strong cash position, BofA Securities said Monday in a report.
Following a review, Keros plans to return $375 million in excess capital to shareholders and move ahead with the development of KER-065 for Duchenne muscular dystrophy. On Monday, activist shareholder ADAR1 Capital Management said the company should return $475 million to investors via a special dividend by the end of Q3.
"To be fair, there were limitations over what the board could do short of dissolving the company," BofA said.
BofA downgraded Keros stock to neutral from buy and lowered the price target to $18 from $32.
Keros shares fell 1.9% in recent Tuesday trading.
Price: 13.83, Change: -0.26, Percent Change: -1.85
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.